Trial Profile
BrUOG 329: Onivyde (Nanoliposomal Irinotecan) and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: A Phase IB/IIA Brown University Oncology Research Group Study
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2021 Results published in the American Journal of Clinical Oncology.
- 31 May 2020 As no antitumor activity was seen in the first 12 patients, the study was terminated as per the results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2020 Status changed from recruiting to discontinued as per the Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.